CRBU vs. MGTX, BDTX, JSPR, CADL, TNYA, SOPH, AVXL, IVVD, TRML, and AURA
Should you be buying Caribou Biosciences stock or one of its competitors? The main competitors of Caribou Biosciences include MeiraGTx (MGTX), Black Diamond Therapeutics (BDTX), Jasper Therapeutics (JSPR), Candel Therapeutics (CADL), Tenaya Therapeutics (TNYA), SOPHiA GENETICS (SOPH), Anavex Life Sciences (AVXL), Invivyd (IVVD), Tourmaline Bio (TRML), and Aura Biosciences (AURA). These companies are all part of the "biological products, except diagnostic" industry.
Caribou Biosciences (NASDAQ:CRBU) and MeiraGTx (NASDAQ:MGTX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, media sentiment, earnings, dividends, analyst recommendations, community ranking and institutional ownership.
Caribou Biosciences currently has a consensus target price of $21.50, indicating a potential upside of 534.22%. MeiraGTx has a consensus target price of $26.00, indicating a potential upside of 355.34%. Given Caribou Biosciences' higher probable upside, research analysts clearly believe Caribou Biosciences is more favorable than MeiraGTx.
MeiraGTx received 170 more outperform votes than Caribou Biosciences when rated by MarketBeat users. Likewise, 71.10% of users gave MeiraGTx an outperform vote while only 53.13% of users gave Caribou Biosciences an outperform vote.
Caribou Biosciences has a beta of 2.56, meaning that its share price is 156% more volatile than the S&P 500. Comparatively, MeiraGTx has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500.
In the previous week, Caribou Biosciences had 7 more articles in the media than MeiraGTx. MarketBeat recorded 8 mentions for Caribou Biosciences and 1 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 0.80 beat Caribou Biosciences' score of 0.28 indicating that MeiraGTx is being referred to more favorably in the news media.
Caribou Biosciences has a net margin of -345.05% compared to MeiraGTx's net margin of -651.19%. Caribou Biosciences' return on equity of -33.42% beat MeiraGTx's return on equity.
77.5% of Caribou Biosciences shares are held by institutional investors. Comparatively, 67.5% of MeiraGTx shares are held by institutional investors. 9.5% of Caribou Biosciences shares are held by company insiders. Comparatively, 9.7% of MeiraGTx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
MeiraGTx has lower revenue, but higher earnings than Caribou Biosciences. MeiraGTx is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.
Summary
Caribou Biosciences beats MeiraGTx on 10 of the 18 factors compared between the two stocks.
Get Caribou Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRBU and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRBU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Caribou Biosciences Competitors List
Related Companies and Tools
